Added value of amyloid PET in individualized risk predictions for MCI patients

INTRODUCTION: To construct a prognostic model based on amyloid positron emission tomography (PET) to predict clinical progression in individual patients with mild cognitive impairment (MCI). METHODS: We included 411 MCI patients from the Alzheimer's Disease Neuroimaging Initiative. Prognostic models were constructed with Cox regression with demographics, magnetic resonance imaging, and/or amyloid PET to predict progression to Alzheimer's disease dementia. The models were validated in the Amsterdam Dementia Cohort. RESULTS: The combined model (Harrell's C = 0.82 [0.78–0.86]) was significantly superior to demographics (β = 0.100, P < .001), magnetic resonance imaging (β = 0.037, P = .011), and PET only models (β = 0.053, P = .003).The models can be used to calculate individualized risk, for example, a female MCI patient (age = 60, APOE ε4 positive, Mini-Mental State Examination = 25, hippocampal volume = 5.8 cm(3), amyloid PET positive) has 35% (19–57) risk in one year and 85% (64–97) risk in three years. Model performances in the Amsterdam Dementia Cohort were reasonable. DISCUSSION: The present study facilitates the interpretation of an amyloid PET result in the context of a patient's own characteristics and clinical assessment.